Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 20/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 7/20 | 0.53 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23267371 | 1.00 | BCL6 (0.56) | BCL6NCOR2ADRB3HTR1DADORA1 | |
| SCHEMBL31595331 | 0.88 | BCL6 (0.58) | BCL6NCOR2ADRB3HTR1DADORA1 | |
| SCHEMBL31595552 | 0.88 | BCL6 (0.58) | BCL6NCOR2ADRB3HTR1DADORA1 | |
| SCHEMBL31595527 | 0.83 | CRBN (0.39) | BCL6 | |
| SCHEMBL23267396 | 0.80 | BCL6 (0.45) | BCL6NCOR2 | |
| SCHEMBL31595767 | 0.80 | BCL6 (0.45) | BCL6NCOR2 | |
| SCHEMBL23267370 | 0.80 | BCL6 (0.58) | BCL6NCOR2ADRB3HTR1DADORA1 | |
| SCHEMBL23267334 | 0.80 | BCL6 (0.58) | BCL6NCOR2ADRB3HTR1DADORA1 | |
| SCHEMBL23267908 | 0.79 | BCL6 (0.56) | BCL6NCOR2 | |
| SCHEMBL31595230 | 0.79 | BCL6 (0.56) | BCL6NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | BCL6 1/4885NCOR2 640/4885ADRB3 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.